1. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin. Chest. 2013; 144: 1555–63. doi: 10.1378/chest.13- 0054.
2. Rosinio S, Keylani AM, D'Agostino DC. Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Inter J Cardiol. 2014; 174: 471- 83. doi: 10.1016/j.ijcard.2014.04.179.
3. Harrington AR, Armstrong EP, Nolan Jr PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676-81. doi: 10.1161/STROKEAHA.111.000402.
4. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation: systematic review. JAMA. 2015; 313 (19): 1950-62. doi: 10.1001/jama.2015.4369.
5. Savelieva I, Camm AJ. Practical Considerations for Using Novel OralAnticoagulants in Patients With Atrial Fibrillation. Clin Cardiol. 2014;37, 1: 32-47. doi: 10.1002/clc.22204.
6. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. doi: 10.1002/14651858.CD000011.
7. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009; 15: e22-e33.
8. Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012; 28: 669-80. doi: 10.1185/03007995.2012.677419.
9. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct Factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104: 1263-71. doi: 10.1160/TH10-05-0328.
10. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012; 18: 527-39. doi: 10.18553/jmcp.2012.18.7.527.
11. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145-53. doi: 10.1093/eurheartj/ehv466.
12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi: 10.1056/NEJMoa1009638.
13. Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol. 2015;38(2):63-8. doi: 10.1002/clc.22373.
14. Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560-6. doi: 10.1002/pds.2109.
15. Laliberte ́F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30:1317-25. doi: 10.1185/03007995.2014.907140.
16. Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30:2461-9. doi: 10.1185/03007995.2014.933577.